Eli Lilly nears deal to buy psychedelic drugmaker AtaiBeckley, Bloomberg News reports
Eli Lilly is entering the psychedelic drug market with a deal to acquire AtaiBeckley for up to $3.8 billion to treat resistant depression.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Eli Lilly is moving to acquire the psychedelic biotech firm AtaiBeckley in a deal valued at up to $3.8 billion. According to reports from Reuters, Bloomberg, and Yahoo Finance, the acquisition is designed to advance therapies for mental health conditions, specifically focusing on treatment-resistant depression. The deal involves the developer of 5-MeO-DMT, as noted by Psychedelic Alpha. While some reports from CNBC and Yahoo Finance initially cited a $2.8 billion figure, other coverage, including that from Bloomberg and Reuters, indicates the total value could reach $3.8 billion. Multiple financial news outlets have highlighted the immediate market reaction to this news. Seeking Alpha reported that AtaiBeckley shares soared 66% amid buyout talks, while Barron's noted a 50% increase in the stock price.
Yahoo Finance further detailed that some venture capitalists anticipate a takeover premium of up to 105% from Eli Lilly. The Financial Times emphasized that AtaiBeckley is a psychedelic biotech firm backed by Peter Thiel. The transaction marks a significant strategic pivot for Eli Lilly as it enters the psychedelic drug race. Context provided by PR Newswire indicates that the primary goal of the acquisition is to develop and advance treatments for individuals who do not respond to traditional depression therapies. The broader industry trend involves experimental psychedelic treatments gaining traction, according to CNBC. AtaiBeckley's position as a developer of 5-MeO-DMT places it at the center of this medical shift, with the world's largest pharmaceutical company, Eli Lilly, now betting on these specific therapies to address unmet needs in mental health care.
Future developments to monitor include the finalization of the acquisition terms and the regulatory path for the 5-MeO-DMT therapies. Market watchers will likely track whether AtaiBeckley stock returns to its four-year highs, a possibility raised by Yahoo Finance. Coverage does not yet specify the exact closing date of the deal or the full list of mental health conditions beyond treatment-resistant depression that the acquired technology will target. Observers will be looking for official confirmation on the final purchase price, given the variance between the $2.8 billion and $3.8 billion figures reported across different outlets.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 115d ago.
Quick answers
How much is Eli Lilly paying for AtaiBeckley?
Reports vary, with CNBC citing $2.8 billion and others, such as Reuters and Bloomberg, stating the deal is for up to $3.8 billion.
What specific condition is the deal intended to treat?
The acquisition aims to advance therapies for treatment-resistant depression and other mental health conditions.
Who is a notable backer of AtaiBeckley?
According to the Financial Times, AtaiBeckley is backed by Peter Thiel.
Coverage (14)
- Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal Reuters · 124d ago
- Eli Lilly buys psychedelic biotech backed by Peter Thiel Financial Times · 124d ago
- Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant depression and other mental health conditions PR Newswire · 125d ago
- ATAI Stock Eyes Rocketing Back To 4-Year Highs: VC Sees Up to 105% Takeover Premium From Eli Lilly Yahoo Finance · 125d ago
- Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction CNBC · 125d ago
- ATAI Stock Soars On Eli Lilly’s $2.8B Buyout Yahoo Finance · 125d ago
- Breaking: World’s Largest Pharmaceutical Company, Eli Lilly, Acquires 5-MeO-DMT Developer AtaiBeckley for Up to $3.8 billion Psychedelic Alpha · 125d ago
- Eli Lilly to buy psychedelic drugmaker AtaiBeckley for up to $3.8 billion in bet on depression therapy Yahoo Finance · 125d ago
- Lilly to Buy Psychedelic Firm AtaiBeckley for Up to $3.8 Billion Bloomberg.com · 125d ago
- Lilly Said to Near Deal for Psychedelic Drugmaker AtaiBeckley Bloomberg.com · 125d ago
- Psychedelic drugmaker AtaiBeckley shares soar 66% on Eli Lilly buyout talks (LLY:NYSE) Seeking Alpha · 125d ago
- This Psychedelic Pharma Stock Is Soaring 50% on Report of Eli Lilly Takeover Talks Barron's · 125d ago
- Here Is Why AtaiBeckley (ATAI) Is One Of The 10 Best Stocks Under $10 That Could Triple Yahoo Finance · 125d ago
- Eli Lilly nears deal to buy psychedelic drugmaker AtaiBeckley, Bloomberg News reports Reuters · 125d ago
Topics
Related trends
Not All Physical Activity Protects Your Brain, Scientists Warn
Scientists warn that not all physical activity protects brain health, while experts advocate for detailed, individualized exercise prescriptions.
The young people caught up in Britain's Neets crisis
A landmark report by former Labour minister Alan Milburn warns that the rising number of young people not in education, employment or training is both an economic and moral crisis for Britain.
Biotech Tops The 'Most Bullish Conversations' And Breaks Out
Biotech markets surge in bullish conversations amid major trial outcomes and regulatory updates from key industry players.
Versant, Lilly put $100 million behind new startup aimed at solving one of gene therapy’s thorniest issues
Seawolf Therapeutics launches with $100 million from Versant Ventures and Eli Lilly to develop non-viral gene therapies targeting obesity, muscle loss, and osteoporosis.
Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn
Johnson & Johnson agreed to buy Texas-based biotech Ollin Biosciences for up to $3.33 billion to expand its eye disease therapies.
Makers of obesity drugs hit back at claims of negative side effects
Makers of obesity drugs defend their product safety amid mounting public scrutiny and reports of side effects.